ReviewCurrent HIV/AIDS reports2010
Role of humoral immunity in host defense against HIV.
Review in Current HIV/AIDS reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- In silico designing of novel epitope-based peptide vaccines against HIV-1.Biotechnology letters · 2024Article
- Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.The Journal of clinical investigation · 2020Article
- Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection.Frontiers in immunology · 2020Article
- Antibody response against koala retrovirus (KoRV) in koalas harboring KoRV-A in the presence or absence of KoRV-B.Scientific reports · 2019Article
- Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-SpecificMolecular & cellular proteomics : MCP · 2019Article
- NK Cells Activated through Antibody-Dependent Cell Cytotoxicity and Armed with Degranulation/IFN-γ Production Suppress Antibody-dependent Enhancement of Dengue Viral Infection.Scientific reports · 2019Article
- Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi.Medical microbiology and immunology · 2018Observational
- HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.PloS one · 2016Article
- Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.Vaccine · 2015Article
- Protective immunity against hepatitis C: many shades of gray.Frontiers in immunology · 2014Review
- Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.Mucosal immunology · 2014Article
- Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women.AIDS research and human retroviruses · 2014Article
- Systems-level analysis of innate immunity.Annual review of immunology · 2014Review
- Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection.Journal of immunological methods · 2013Article
- Infection with feline immunodeficiency virus alters intestinal epithelial transport and mucosal immune responses to probiotics.Veterinary immunology and immunopathology · 2013Article
- Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals.AIDS research and human retroviruses · 2013Article
- A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.PloS one · 2013Article
- Significant increase in cytotoxic T lymphocytes and natural killer cells by triphala: a clinical phase I study.Evidence-based complementary and alternative medicine : eCAM · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Individuals infected with HIV-1 and nearly everyone vaccinated with HIV-1 vaccines will, in time, generate antibodies against viral proteins. These antibodies do not resolve natural infection, and vaccine candidates that successfully stimulate the production of high titers of neutralizing antibodies have failed to protect against infection. In spite of this, antibodies continue to be a focus of vaccine research. One reason for the continued interest in antibodies is the failure of a vaccine engineered to generate cell-mediated immunity against HIV. Successful protective immunity against most intracellular pathogens involves several arms of the immune response. A successful vaccine should also stimulate both protective cell-mediated immunity and specific antibody. Efforts should be directed toward making a vaccine that will stimulate the production of 1) more antibody, 2) more broadly cross-reactive neutralizing antibody (broadly neutralizing antibodies), and 3) antibody with a particular functional activity (antibody-dependent cell-mediated cytotoxicity; catalytic antibodies).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.